MDmune, Joint Drug Delivery System Research with French Vect-Horus

[Asia Economy Reporter Jihee Kim] MD Immun announced on the 6th that it has signed a joint research and development contract for a drug delivery system (DDS) for central nervous system diseases with Vect-Horus, based in Marseille, France.

Vect-Horus is a biotechnology company specializing in vector design and synthesis. It possesses the VECTrans® technology, which aids in delivering various drugs and diagnostic substances not only across the blood-brain barrier (BBB) but also to various human tissues. The BBB is a structure that protects key regulatory centers from potential harmful pathogens or substances in the blood. For polymers or hydrophilic drugs to pass through the BBB, a special carrier-type DDS is required.

MD Immun and Vect-Horus aim to develop a next-generation drug delivery system that accurately exerts effects in the brain with only a minimal amount of drug by integrating VECTrans® onto the surface of MD Immun’s cell-derived vesicles (CDV).

Alexandre Tokay, CEO of Vect-Horus, stated, “We are proud to create technological synergy by combining VECTrans® technology with MD Immun’s CDV-based biodrone platform technology,” and added, “We expect new research results that enable drug delivery to the brain through this joint project.”

MD Immun’s CSO Seungwook Oh said, “Through the innovative technological synergy of both companies, we will not only enhance the BBB penetration effect of CDV but also contribute to overcoming the greatest challenges in developing new drugs for the central nervous system.”

This content was produced with the assistance of AI translation services.